Anti-migration and anti-invasion effects of 2-hydroxy-6-tridecylbenzoic acid is associated with the enhancement of CYP1B1 expression through activating the AMPK signaling pathway in triple-negative breast cancer cells. Issue 24 (17th December 2021)

• Record Type: Journal Article
• Authors: Zhou, Dayu; Zhao, Xiaohui; Yu, Mingxi; Xu, Yan; Fu, Chenghao; Zheng, Kexin; Xia, Chao; Huang, Bo; Ma, Shiliang
• Is Part Of: Natural product research. Volume 35:Issue 24(2021)
• Page Start: 5924
• Page End: 5928
• Publication Date: 2021-12-17
• Subjects: Triple-negative breast cancer -- 2-hydroxy-6-tridecylbenzoic acid -- CYP1B1 -- AMPK -- migration -- invasion; Natural products -- Periodicals; Natural products -- Research -- Periodicals; Biological Factors -- Periodicals; Biological Products -- Periodicals; 547
• DOI: 10.1080/14786419.2020.1803310
• Languages: English
• ISSNs: 1478-6419

Abstract

Abstract: 2-hydroxy-6-tridecylbenzoic acid is alkylsalicylic acid monomer compound, abundantly existed in the ginkgo biloba extracts, however, the underlying mechanism of its anti-migration and anti-invasion effects in triple-negative breast cancer (TNBC) is not clear. Here, 2-hydroxy-6 -tridecylbenzoic acid inhibited MDA-MB-231 and 4 T-1 cells growth without toxicity to MCF-10A normal breast cells. Meanwhile, 2-hydroxy-6-tridecylbenzoic acid inhibited cells migration and invasion as well as EMT with the increase of E-cadherin expression accompanied by the decrease of N-cadherin, Vimentin, Snail, MMP-2 and MMP-9 expression. The inhibition was further demonstrated by the enhancement of cytochrome P450 (CYP) 1B1 expression through the activation of AMP activated protein kinase (AMPK) in MDA-MB-231 and 4 T-1 cells. Silencing of CYP1B1 and AMPK with siRNA blocked the inhibitory effects of migration and invasion, and reversed the EMT related genes. These findings may provide a novel mechanism of the 2-hydroxy-6-tridecylbenzoic acid as a molecular-targeted therapeutic drug for TNBC patients. Graphical Abstract: UF0001